Articles mentioning Bristol-Myers Squibb Co. (BMY)

Results 11 - 20 of 750 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY

Investing | November 10, 2014

3 Drugs That Make Gilead Sciences' Harvoni Look Cheap

Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.

Investing | November 05, 2014

Why Bristol-Myers Squibb Co. Leaped 15% Higher in October

Bristol-Myers Squibb was among the best performing pharmaceutical stocks in October, launching 15% higher and tacking on more than $12 billion in market value. Find out what sent Bristol-Myers' shares soaring higher and whether or not it'll continue.

Investing | October 15, 2014

Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg

Bristol-Myers Squibb's Opdivo and Merck's Keytruda are sought after drugs for combination cancer treatments.

Investing | October 05, 2014

Why Johnson & Johnson, Bristol-Myers Squibb, and Pfizer Care So Much About This Tiny Biotech Company

Johnson & Johnson, Bristol-Myers Squibb, and Pfizer could see sales of their factor Xa drugs Xarelto and Eliquis jump if Portola Pharmaceuticals antidote succeeds in trials.

Dividends & Income Investing | October 04, 2014

Better Dividend Stock: Merck & Co. Inc. or Bristol-Myers Squibb Co.?

S&P 500 companies paid out $91.5 billion in dividends last quarter. Unfortunately, not all dividend stocks are created equally. Let's examine two of Big Pharma's highest-yielding stocks to determine which is the better dividend stock.

Investing | September 04, 2014

Bristol-Myers Squibb's Eliquis Takes Aim at Johnson & Johnson

Sales of Bristol-Myers Squibb and Pfizer's Eliquis are heading higher, threatening Johnson & Johnson's market leadership among factor Xa anticoagulant drugs.

Investing | July 24, 2014

Bristol-Myers Squibb's Second-Quarter Reflects a Company in Transition

Bristol-Myers Squibb revenue fell by 4% in the second quarter, due mostly to its exit from the diabetes market.

Investing | July 15, 2014

2 Reasons to Watch Bristol-Myers Squibb Co

Bristol-Myers Squibb is winning big in Japan, can they bring that success home?

Investing | July 12, 2014

This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something

Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.

Investing | July 07, 2014

Is Bristol-Myers Squibb Co. Destined for Greatness?

Let's see what the numbers say about Bristol-Myers Squibb (BMY).

Results 11 - 20 of 750 : Previous 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for BMY


Advertisement